Claims for Patent: 6,627,189

Summary for Patent: 6,627,189

Title:	Inhibition of cellular proliferation using ras antisense molecules
Abstract:	Disclosed are methods and compositions for the selective inhibition gene expression through the application of antisense RNA technology. Antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged. A three-fold growth inhibition occurred in H460a cells when expression of the mutated ras p21 protein was down-regulated by antisense RNA and cells remained viable. The growth of H460a tumors in nu/nu mice was substantially reduced by expressed K-ras antisense RNA.
Inventor(s):	Roth; Jack A. (Houston, TX), Mukopadhyay; Tapas (Houston, TX), Tainsky; Michael (Houston, TX)
Assignee:	Board of Regents, The University of Texas Systems (Austin, TX)
Application Number:	08/459,699
Patent Claims:	1. A method for selectively inhibiting the expression of a human p21 K-ras product in a human cell, the method comprising: (a) providing a viral vector comprising a promoter and a nucleic acid segment that comprises sequences that are complementary to and hybrizide with an intron region and a flanking exon region of the human p21 K-ras oncogene, wherein the intron region is distinct from that found in an intron of H-ras or N-ras, said nucleic acid segment positioned antisense to said promoter; and (b) contacting the viral vector with the cell in an amount effective to inhibit the expression of the K-ras gene product. 2. The method of claim 1, wherein the nucleic acid segment comprises sequences from exons II and III and intron I of the K-ras oncogene. 3. The method of claim 2, wherein the viral vector is a retrovirus, an adenovirus, an adeno-associated virus or a vaccinia virus. 4. A method for the inhibition of tumorigenicity of a K-ras-transformed human cancer cell comprising: (a) providing a viral expression vector that expresses an antisense RNA molecule which comprises: (i) an intron region of the human p2 K-ras oncogene that is not found in an intron of H-ras or N-ras; (ii) and a flanking exon region of the human p21 K-ras oncogene and; (b) introducing the viral vector into the cancer cells under conditions allowing the expression of the antisense RNA in amounts effective to inhibit the tumorigenicity of the cancer cells. 5. The method of claim 4, wherein the antisense RNA comprises sequences complementary to intron II of the p21 K-ras oncogene. 6. The method of claim 4, wherein the antisense RNA comprises sequences complementary to exons II and III and intron II of K-ras. 7. A method of screening for selective inhibition of a ras gene product in a human cell, the method comprising: (a) testing the cell to determine the identity of the ras gene to be inhibited; (b) preparing an antisense molecule which comprises a sequence that is complementary and hybridizes to a distinct intron region and flanking exon region of the identified human ras gene; (c) introducing the antisense molecule into the cell in amounts effective to selectively inhibit the selected ras gene; and (d) assessing the effect of the antisense molecule on ras expression. 8. The method of claim 7, wherein the identified ras gene is a ras oncogene. 9. The method of claim 8, wherein the identified ras gene is a K-ras, H-ras or N-ras oncogene. 10. The method of claim 9, wherein the identified ras gene is a K-ras oncogene. 11. The method of claim 7, further comprising the steps of: (a) preparing a recombinant vector which comprises the antisense molecule and encodes an antisense RNA; and (b) introducing the recombinant vector into the cell in a manner which allows the expression of the encoded antisense RNA therein at a level sufficient to inhibit said expression. 12. The method of claim 11, wherein the recombinant vector stably integrates into the cell. 13. A method for selectively inhibiting the growth of a human tumor cell, the method comprising: (a) providing a viral vector comprising a promoter and a nucleic acid segment that comprises sequences that are complementary to and hybridize with an intron region and flanking exon region of the human p21 K-ras oncogene, wherein the intron region is distinct from that found in an intron of H-ras or N-ras, said nucleic acid segment positioned antisense to said promoter; and (b) contacting the viral vector with the tumor cell in an amount effective to inhibit the expression of the K-ras gene product whereby the inhibition of expression of the K-ras gene product inhibits the growth of said tumor cell. 14. A method for selectively inhibiting the growth of a human tumor, the method comprising: (a) providing a viral vector comprising a promoter and a nucleic acid segment that comprises sequences that are complementary to and hybridize with an intron region and flanking exon region of the,human p21 K-ras oncogene, wherein the intron region is distinct from that found in an intron of H-ras or N-ras, said nucleic acid segment positioned antisense to said promoter; and (b) contacting the viral vecotor with the tumor in an amount effective to inhibit the expression of the K-ras gene product whereby the inhibition of expression of the K-ras gene product inhibits the growth of said tumor.

Details for Patent 6,627,189

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-09-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-09-30
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-09-30